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Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD), accounting for 30% of incident cases in the UK and 29% in Europe in 20181,2. As the prevalence 
of type 2 diabetes increases, the number of people with diabetes and 
ESRD requiring renal replacement therapy is also rising1. A scarcity 
of organs for transplantation as well as cardiovascular comorbidities 
associated with diabetes that preclude transplantation mean that 
hemodialysis or peritoneal dialysis are the only available treatment 
options for many.
ESRD and dialysis itself increase the risk of hypoglycemia and 
hyperglycemia, which are associated with adverse outcomes3–5. 
Management of diabetes in this population is challenging for both 
patients and healthcare professionals. Many aspects of diabetes care 
of patients on dialysis are poorly understood, including targets for 
glycemic control and treatment algorithms6,7. Most oral diabetes 
medications are contraindicated in people with ESRD, so insulin 
is the most commonly used diabetes therapy. Optimal insulin 
dosing regimens are difficult to establish with the altered glucose 
and insulin metabolism associated with ESRD and dialysis5, and 
concerns regarding hypoglycemia often result in sub-optimal 
glycemic control. There is an unmet need for novel approaches 
to the safe and effective management of diabetes for people 
requiring dialysis.
Closed-loop insulin delivery systems comprise a continuous 
glucose monitor, an insulin pump and a control algorithm that 
continuously and automatically modulates subcutaneous insulin 
delivery in response to real-time interstitial glucose concentrations8. 
Closed-loop systems are increasingly being applied to the manage-
ment of type 1 diabetes. However, use of this technology in people 
with type 2 diabetes has been limited to the inpatient setting includ-
ing those on hemodialysis9–12. Safety and efficacy in outpatient 
settings, a precursor for wider clinical acceptance, is to be deter-
mined. In the present study, we address this issue and hypothesize 
that fully closed-loop insulin delivery may improve glycemic control 
compared to standard insulin therapy without increasing the risk of 
hypoglycemia in people with type 2 diabetes and ESRD undergoing 
maintenance dialysis in the outpatient setting.
Results
Study participants. From 21 October 2019 to 3 November 2020, 
27 participants were enrolled and randomized (17 men, 9 women, 
average age 68 ± 11 years (mean ± s.d.) and average diabetes dura-
tion 20 ± 10 years; one participant died prior to starting the first 
treatment arm; Fig. 1b). Baseline diabetes regimen details are shown 
in Supplementary Table 1. Thirteen participants were randomized 
to receive closed-loop first (Extended Data Fig. 1) and thirteen were 
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randomized to standard insulin therapy first. Recruitment stopped 
early due to Brexit-related sponsorship issues and delays and con-
straints caused by COVID-19 (Methods). The flow of participants 
through the trial is shown in Fig. 1a. Of 27 randomized participants, 
one participant was withdrawn from the study post-randomization 
as they required hospital admission and died before the start of 
the first intervention period (control). Two participants stopped a 
study period early, one during the second period (control) due to 
bereavement and one during the first period (closed-loop) due to 
local COVID-19 restrictions. These participants both completed a 
minimum of 48 h in both study periods and were included in the 
analysis. The average washout period was 17 ± 5 days, overall. The 
washout period in those receiving closed-loop first was 16 ± 4 days, 
and was 17 ± 5 days in those receiving usual care first.
Efficacy. Primary and secondary endpoints calculated using data 
from all randomized subjects with at least 48 h of available data in 
both study periods (n = 26) are presented in Table 1. The primary 
endpoint, the proportion of time sensor glucose was in the target 
glucose range between 5.6 and 10.0 mmol l−1, was greater during 
closed-loop use than with standard insulin therapy (52.8 ± 12.5% 
versus 37.7 ± 20.5% for closed-loop versus control, respectively; 
67 approached to participate
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Fig. 1 | Overview of the trial and participants. a, Overview of the participant flow. b, Baseline characteristics of the study participants.
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P < 0.001), with a mean difference of 15.1 percentage points in 
favor of closed-loop (95% CI 8.0–22.2). The time in range with 
closed-loop in period 1 was 54.4 ± 12.1% and in period 2 was 
51.2 ± 13.3%. The time in range with standard insulin therapy 
in period 1 was 37.1 ± 22.9% and was 38.3 ± 18.6% in period 2. 
No period effect was observed (P = 0.86).
Mean glucose was lower with closed-loop than control 
(10.1 ± 1.3 versus 11.6 ± 2.8 mmol l−1 respectively; mean differ-
ence of 1.5 mmol l−1 (95% CI 0.6–2.5); P = 0.003). Figure 2 shows 
the 24-h sensor glucose profiles. The time spent in hypoglycemia 
(sensor glucose <3.9 mmol l−1) was reduced with closed-loop versus 
control (median (IQR) 0.12 (0.02–0.44%) versus 0.17 (0.00–1.11%); 
P = 0.040; Fig. 2b).
The standard deviation of glucose was lower during closed-loop 
than during the control period (3.2 ± 0.7 versus 3.6 ± 0.9 mmol l−1; 
P = 0.021) but there was no significant difference in the within-day 
or between-day coefficient of variation of glucose between inter-
ventions (Table 1). Total daily insulin doses were similar between 
interventions.
Closed-loop performance improved from days 1–7 to days 8–20, 
as shown by an increase in the time spent in the target glucose range 
by 8.1 percentage points (47.6 ± 16.1 versus 55.8 ± 12.6 mmol l−1; 
Fig. 3). Mean glucose and time in hyperglycemia (sensor glucose 
>10 mmol l−1) both decreased during days 8–20 without any dif-
ference in time spent in hypoglycemia or total daily insulin dose 
(Supplementary Table 2). There was no difference in key glyce-
mic outcomes between days 1–7 and days 8–20 during the control 
period, but measures of glycemic variability increased during days 
8–20 compared with days 1–7 inclusive (Supplementary Table 2).
There were no differences in any glycemic outcomes, including 
measures of variability between dialysis days and non-dialysis days 
during either intervention period (Table 2). Closed-loop driven 
insulin delivery was lower on dialysis days than on non-dialysis 
days (0.29 (0.13, 0.51) versus 0.31 (0.16, 0.53) U kg−1, respectively; 
Table 2). There was no difference in the mean inter-dialytic weight 
gain between interventions (closed-loop 1.8 ± 1.2 versus control 
1.7 ± 1.1 kg; P = 0.55).
The closed-loop algorithm glucose target was set at 7.3 (7.0, 
8.0) mmol l−1. The proportion of time spent in the target glucose 
range decreased as the glucose target setting increased (Extended 
Data Fig. 2).
Safety. One episode of severe hypoglycemia occurred during the 
closed-loop period, but closed-loop had not been in operation at 
the time of the event or for 24 h previously. Six other serious adverse 
events were reported (Table 3). Two of these occurred during the 
closed-loop period (reduced responsiveness on dialysis requir-
ing hospital admission and COVID-19 infection requiring hospi-
tal admission), two events occurred during washout or pre-study 
start (one hospital admission for bowel obstruction resulting in 
death and one hospital admission for diabetic foot-related cellulitis 
requiring intravenous antibiotics), and two events occurred during 
the control period (one below-knee amputation due to diabetic foot 
ulceration, and one hospital admission with an ischemic stroke). 
None of the serious adverse events were deemed related to study 
devices or study procedures.
Nine other adverse events were reported (Table 3), five of which 
occurred during closed-loop, two during the control period and 
two during washout or pre-study arm start. Three of these events 
were deemed related to study devices or study procedures (two skin 
reactions from the infusion sets and one infusion set failure causing 
hyperglycemia). Six device deficiencies occurred during the entire 
study (three sensor-related, one phone/receiver-related and two 
closed-loop initiation errors), none of which led to an adverse event.
Utility evaluation and diabetes burden. Glucose sensor and 
closed-loop usage were high in the study, at 95% (94, 96) and 93% 
(89, 94), respectively. The hypoglycemia confidence score was higher 
with the closed-loop system than with standard insulin therapy (3.8 
versus 3.5, P = 0.013), but there was no difference between interven-
tions in the hypoglycemia worry score or diabetes burden measured 
by the ‘problem areas in diabetes’ (PAID) survey (Supplementary 
Table 3). The PAID score in both periods of the study was low 
(7.5 for control, 10.0 for closed-loop; highest score of 100.0).
All responders (n = 24) reported that they were happy to have 
their glucose levels controlled automatically by the closed-loop 
system and would recommend the closed-loop system to others. 
Ninety-two percent (n = 22) reported that they spent less time 
managing their diabetes with the closed-loop system than in the 
control period, and 87% (n = 21) were less worried about their 
glucose levels with the closed-loop system than with standard 
insulin therapy (Supplementary Table 4). Fifty percent (n = 12) of 
responders reported improved sleep and 8% (n = 2) reported worse 
sleep while using closed-loop.
Benefits of the closed-loop system reported by study participants 
included a reduced need for finger-prick glucose checks, less time 
required to manage diabetes, resulting in more personal time and 
freedom, and improved peace of mind and reassurance. Device 
burden and discomfort wearing the insulin pump and carrying the 
smartphone were the most common limitations reported by partici-
pants (Supplementary Table 4).
Table 1 | Comparison of primary and secondary outcomes 
between closed-loop and control periods
Closed-loop 
(n = 26)
Control (n = 26) P value
Proportion of time spent 
at glucose level (%)
 5.6–10.0 mmol l−1 a 52.8 (12.5) 37.7 (20.5) <0.001
 3.9–10.0 mmol l−1 57.1 (14.3) 42.5 (24.7) 0.002
 >10.0 mmol l−1 42.6 (14.3) 56.6 (25.1) 0.003
 >20.0 mmol l−1 1.8 (2.4) 6.7 (10.7) 0.012
 <5.6 mmol l−1 3.2 (2.0, 7.0) 4.0 (0.9, 9.5) 0.87
 <3.9 mmol l−1 0.12 (0.02, 0.44) 0.17 (0.00, 1.11) 0.040
 <3.0 mmol l−1 0.00 (0.00, 0.03) 0.00 (0.00, 
0.22)
0.047
Mean glucose (mmol l−1) 10.1 (1.3) 11.6 (2.8) 0.003
Standard deviation of 
glucose (mmol l−1)
3.2 (0.7) 3.6 (0.9) 0.021
CV of glucose (%) 31.7 (4.8) 31.5 (5.4) 0.87
Between days CV of 
glucose (%)
30.8 (3.4) 31.2 (5.8) 0.72
Total daily insulin dose 
(U kg−1)
0.34 (0.15, 0.54) 0.36 (0.19, 0.58) 0.37
Total daily insulin  
dose (U)
20.4 (9.2, 50.3) 32.2 (12.1, 54.4) 0.38
Sensor glucose data (h) 454 (450, 460) 452 (425, 454) 0.062
Time using sensor  
glucose (%)
95 (94, 96) 94 (90, 95) 0.062
Time using closed-loop 
(%)
93 (89, 94) – –
aPrimary endpoint. Data presented as mean (s.d.) or median (interquartile range). CV, coefficient 
of variation. A two-sample t-test on paired differences was used to compare normally distributed 
variables and the Mann–Whitney–Wilcoxon rank-sum test was used for data that are not normally 
distributed. No allowance was made for multiplicity.
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Discussion
This study provides evidence that fully closed-loop insulin delivery 
can improve glucose control and reduce hypoglycemia compared to 
standard insulin therapy in adults with type 2 diabetes and ESRD 
requiring dialysis, in an unrestricted home setting. We have shown 
that the fully closed-loop system has the potential to safely and 
effectively manage glucose levels in one of the most vulnerable sub-
populations with type 2 diabetes where the risk of glycemic compli-
cations and diabetes-related adverse events is greatest.
Compared with control therapy, fully closed-loop insulin 
delivery was associated with over 3.5 additional hours every day 
spent in the target glucose range. The efficacy of closed-loop 
directed insulin delivery improved considerably over the study 
period with algorithm adaptation, and time in the target glucose 
range increased from 36% on day 1 to over 60% by the end of 
the 20-day intervention period (Fig. 3). This finding highlights the 
importance of an adaptive algorithm that can adjust in response 
to individuals’ changing insulin requirements over time, indepen-
dent of its initialization. This pattern of incremental improvements 
in time in range with increasing duration of wear time has been 
reported previously with this fully closed-loop system in the inpa-
tient setting10. It is reasonable to postulate that time in target range 
could improve further with a longer duration of use. It has previ-
ously been reported that 26 days of closed-loop use are required for 
the proportion of time in target glucose range to plateau, although 
this is likely to be population-dependent13,14.
In this study, the proportion of time in target range with 
closed-loop was lower than observed in a retrospective analysis of 
inpatients requiring hemodialysis using the same algorithm in a 
hospital setting (53% versus 69%, respectively)12. A higher glucose 
target was applied in the present study (median 7.3 mmol l−1 versus 
5.8 mmol l−1), given the vulnerable population, which probably 
contributed to the reduced time in target glucose range observed. 
Higher glucose target settings were associated with less time in 
target glucose range (Extended Data Fig. 2). However, time spent in 
hypoglycemia did not increase with lower personal glucose targets, 
suggesting that the glucose target does not need to be unnecessarily 
elevated.
The reduction in time in hypoglycemia observed with closed-loop 
is clinically important in this highly vulnerable population with 
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Fig. 2 | Glycemic outcomes during closed-loop and control periods. a, Median and IQR of sensor glucose during the closed-loop period (solid red line 
and pink shaded area) and control period (solid gray line and gray shaded area) from midnight to midnight. n = 26 biologically independent samples. The 
lower and upper limits of the glucose target range, 5.6–10.0 mmol l−1, are denoted by the horizontal dashed lines. b, Individual participants’ time spent with 
glucose in the target glucose range of 5.6–10.0 mmol l−1 (left; overall mean shown in red) and with glucose in hypoglycemia <3.9 mmol l−1 (right; overall 
median shown in red) during control and closed-loop therapy.
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a high burden of comorbidities. Closed-loop was associated with 
very low time in hypoglycemia (0.12% time spent with glucose 
<3.9 mmol l−1), despite accommodating the glycemic excursions 
associated with end-stage renal failure and dialysis. Hypoglycemia 
exposure during the control period was also low, in contrast with 
the high frequency of hypoglycemia reported in other studies15,16. 
The greatest reductions in hypoglycemia with closed-loop were 
observed in participants with the highest levels of hypoglycemia 
during the standard insulin therapy period (Fig. 2b). Hypoglycemia 
is a considerable barrier to optimization of insulin therapy. The 
risk of hypoglycemia is high in this population, and people on 
dialysis often have impaired awareness of hypoglycemia17. 
Hypoglycemia has been associated with an increased risk of 
all-cause mortality in those with diabetes on dialysis, but causation 
has not been established17.
The improved time in target glucose range observed with 
closed-loop was predominantly due to the reduced time spent in 
hyperglycemia. Time spent with glucose levels in severe hypergly-
cemia (>20.0 mmol l−1) was also reduced with closed-loop therapy. 
This degree of hyperglycemia is associated with both acute and 
chronic complications.
The closed-loop algorithm was able to manage fluctuations in 
glucose and insulin kinetics between dialysis and non-dialysis days 
effectively. There was no difference in glucose outcomes between 
dialysis and non-dialysis days, but closed-loop insulin delivery 
was lower on dialysis days than non-dialysis days, an effect that is 
probably related to the impact of the dialysate glucose concentration 
on blood glucose concentrations.
Closed-loop insulin delivery was safe in this vulnerable popu-
lation. Although there was one severe hypoglycemia episode 
during the closed-loop arm, this occurred when closed-loop had 
not been in operation for over 24 h. No study-related serious adverse 
events occurred during the closed-loop intervention period, and 
the commonest study-related adverse events were self-limiting skin 
reactions.
Closed-loop and sensor glucose usage were high in the study, 
supporting acceptability of this approach in this population. All 
study participants were happy to have glucose levels managed with 
an automated insulin delivery system and would recommend its use 
to others. Participants felt more confident in managing hypoglyce-
mia with the closed-loop system, although this could be due to the 
availability of real-time glucose levels and alarms for hypoglycemia. 









































































Fig. 3 | Daily trend of the proportion of time when sensor glucose was in the target range for the two treatments. Daily trend of the proportion of  
time when sensor glucose was in the target range between 5.6 and 10.0 mmol l−1 during the closed-loop period (black bars) and the control period  
(gray shaded bars). n = 26 biologically independent samples. Mean and s.d. are shown.
Table 2 | Dialysis day and non-dialysis day outcomes during 
closed-loop and control periods









Time spent  
at glucose  
levels (%)
5.6–10.0 mmol l−1 53.9 (14.7) 37.2 (20.3) 51.9 (12.5) 36.3 (22.2)
>10.0 mmol l−1 41.0 (16.2) 56.2 (24.9) 43.5 (14.4) 58.8 (26.5)












2.8 (0.7) 3.2 (0.9) 2.8 (0.6) 3.0 (0.8)
CV of glucose 
(%)
27.4 (4.7) 27.8 (5.6) 28.0 (3.1) 26.1 (6.9)










an = 25, as one participant receiving peritoneal dialysis was excluded from this analysis. Data 
presented as mean (s.d.) or median (interquartile range). CV, coefficient of variation.
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Device burden was reported as the main perceived drawback to this 
approach.
The strengths of this study include the multinational random-
ized crossover design, the fully closed-loop approach adopted and 
the unrestricted and unsupervised home setting, including dialysis 
sessions.
Limitations include the smaller sample size than planned due 
to Brexit-related study sponsorship issues and the COVID-19 pan-
demic. Device management was performed by the study team to 
minimize training burden and therefore we cannot comment on the 
competency of this population to self-manage this treatment modal-
ity. Diabetes therapies during the control period were not standard-
ized or optimized during the trial. We did not evaluate the accuracy 
of the glucose sensor in the present study; however, because the 
same sensor was used during both study arms, we believe this is 
unlikely to have impacted the results. As this was an exploratory 
study, no adjustment was made for multiple comparisons in the 
statistical analysis. We included only one participant receiving 
peritoneal dialysis, thus limiting interpretation of efficacy and safety 
in this specific cohort.
Our study evaluated the performance of a fully closed-loop 
system in an unrestricted outpatient setting in a highly vulnerable 
population with type 2 diabetes and end-stage renal failure requir-
ing dialysis. Having demonstrated safety and efficacy in this at-risk 
population in this exploratory study, larger studies are now required 
to confirm these findings and to determine if the glycemic improve-
ments observed with closed-loop are associated with a reduction 
in complications and improved quality of life, as well as whether 
closed-loop should be targeted towards specific subpopulations (for 
example, those with high hypoglycemic burden or peri-transplant). 
We suggest that the fully closed-loop approach may also be bene-
ficial in the wider population of people with type 2 diabetes, and 
further studies are warranted.
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Number of severe hypoglycemia 
events
1 1 0
Number (%) of participants with 
severe hypoglycemic events
1 (4) 1 (4) 0 (0)
Number of serious adverse events 
(not study-related)
7 3 2
Number (%) of participants with 
serious adverse events
6 (22) 3 (12) 2 (8)
Number of other adverse events 9 5 2
Number (%) of participants with 
adverse events
7 (26) 4 (15) 2 (8)
Number of device deficiencies 6 5 1
Number (%) of participants with 
device deficiencies
6 (22) 5 (19) 1 (4)
Severe hypoglycemia is defined as capillary glucose < 2.2 mmol l−1 or requiring assistance of 
another person.
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Methods
Trial design and participants. The trial adopted an open-label, two-center, 
multinational, randomized, two-period crossover design contrasting fully 
closed-loop glucose control using faster-acting insulin aspart (Fiasp, Novo 
Nordisk) (‘closed-loop’) and standard multiple daily insulin injection therapy 
(‘control’) during unrestricted living. Each intervention period lasted 20 days, 
separated by two to four weeks of washout using pre-study treatment. The order of 
the two interventions was random.
Participants were recruited from dialysis centers and nephrology and diabetes 
outpatient clinics at Addenbrooke’s Hospital in Cambridge, United Kingdom, and 
Inselspital, University Hospital of Bern, Switzerland. Inclusion criteria included 
age 18 years and older, type 2 diabetes requiring subcutaneous insulin therapy and 
end-stage renal failure requiring maintenance dialysis (hemodialysis or peritoneal 
dialysis). Exclusion criteria included type 1 diabetes, pregnancy or breast-feeding, 
severe visual or hearing impairment and any physical or psychological disease, 
or the use of medication(s) likely to interfere with the conduct of the trial or 
interpretation of the results.
Written informed consent was obtained from all participants prior to the start 
of study-related procedures. The study protocol was approved by the local research 
ethics committees (London–Stanmore Ethics Committee, UK; Ethics Committee 
Bern, Switzerland) and regulatory authorities (MHRA and Swissmedic). The full 
trial protocol is available in the Supplementary Note. The safety aspects of the trial 
were overseen by an independent Data and Safety Monitoring Board. The study 
was registered 19 July 2019 with ClinicalTrials.gov NCT04025775.
Protocol adherence. There were 25 protocol deviations during the study period, 
including seven COVID-19-related deviations (delay to starting or premature 
finishing of a study period), seven home visits to replenish insulin supplies and 11 
visits to replace infusion sets, sensors or batteries.
Recruitment was stopped early due to Brexit-related sponsorship issues that 
prevented the Switzerland site from recruiting any further participants after 31 
December 2020, and UK study personnel were working clinically in high-risk 
COVID-19 environments that could have put study participants at increased risk.
Randomization and masking. Eligible participants were randomly assigned to 
either initial use of fully closed-loop glucose control with faster-acting insulin aspart 
for 20 days followed by standard multiple daily insulin injection therapy for 20 days, 
or vice versa. Randomization was done using a computer-generated sequence with 
a permuted block design (block size 4) and stratified by center. Participants and 
investigators were not masked to the intervention being used during each period 
due to the nature of the interventions precluding the ability to mask.
Procedures. Participant demographics and medical history, body weight and 
height, glycated hemoglobin (HbA1c) and total daily insulin dose were recorded  
at enrollment.
Body weight pre- and post-dialysis was recorded at each dialysis session  
(or daily if on peritoneal dialysis) as per usual clinical practice. All participants 
dialyzed with 5.5 mmol l−1 glucose-containing dialysate. Fingerstick capillary 
glucose measurements were performed by dialysis staff according to usual  
clinical practice.
Closed-loop insulin delivery system. The CamAPS HX closed-loop app 
(CamDiab) resides on an unlocked Android phone, receives sensor glucose data 
from a Dexcom G6 transmitter (Dexcom) and uses the Cambridge adaptive model 
predictive control algorithm (version 0.3.71) to direct insulin delivery on a Dana 
Diabecare RS pump (Diabecare; Extended Data Fig. 1). Every 8 to 12 min, and 
based on sensor glucose data, the Cambridge adaptive control algorithm calculates 
an insulin infusion rate that is communicated wirelessly to the insulin pump. 
Sensor glucose and insulin data are automatically uploaded to the Diasend/Glooko 
(https://diasend.com//en) data management platform.
The control algorithm is initialized using the participant’s weight and total 
daily insulin dose and gradually adapts its insulin dosing based on observed 
glucose patterns. The nominal glucose target is 5.8 mmol l−1 and can be adjusted as 
required between 4.4 and 11.0 mmol l−1. In the present study, given the vulnerable 
population, the glucose target was set at 7.0 mmol l−1 and above, based on 
individual circumstances. Low glucose alarms were customized at a threshold to 
suit the participant.
Closed-loop period. Participants’ usual insulin therapy was discontinued on the 
day of closed-loop initialization. All other medications were continued.
Closed-loop insulin delivery was continued for 20 days, including during 
dialysis sessions. Faster-acting insulin aspart (Fiasp) was delivered via the insulin 
pump throughout the closed-loop study period. Fiasp was used for its properties 
of faster onset and offset of action, and its potential to enhance closed-loop 
performance. No prandial insulin boluses were delivered and the control algorithm 
was not aware of timing or carbohydrate content of meals. Infusion sets were 
changed at each dialysis session by the study team.
Participants were unrestricted in relation to their usual activity and dietary 
intake. The study did not interfere with or specify the medications prescribed 
by the local clinical team. All participants were provided with a 24-h telephone 
helpline to contact the local study team in the event of study-related issues. At the 
end of the closed-loop period, devices were removed and participants’ usual insulin 
therapy re-started.
Standard insulin therapy period. During the control period, participants’ received 
their usual insulin therapy and other diabetes medications. Fingerstick capillary 
glucose measurements were performed by participants as per usual clinical 
practice. Glycemic management was performed by the clinical team according to 
local practice. A continuous glucose sensor, Dexcom G6 (Dexcom), was inserted by 
the study team on the first day of the study arm. The continuous glucose monitor 
receiver was modified to mask the sensor glucose concentration to the participant 
and investigators.
Participants were unrestricted in relation to their usual activity and dietary 
intake. The study did not interfere with or specify the medications prescribed 
by the local clinical team. All participants were provided with a 24-h telephone 
helpline to contact the local study team in the event of study-related issues. At the 
end of the standard insulin therapy period, the glucose sensor was removed.
Questionnaires. Participants were invited to complete the validated questionnaires 
at the end of each study period: the PAID questionnaire to assess diabetes distress, 
the Hypoglycaemia Confidence Survey to evaluate perceptions of ability to 
self-manage hypoglycemia and the Hypoglycaemia Fear Survey-II Worry Scale 
HFS-W to estimate hypoglycemia-related fear and anxiety (Cambridge only)18–20. 
Additionally, participants filled in a closed-loop experience questionnaire 
collecting feedback on satisfaction with closed-loop therapy, acceptance of wearing 
study devices and recommending closed-loop to others.
Sample size. This was an exploratory study aiming for 32 subjects with at least 48 h 
of data. Because previous studies using closed-loop in an inpatient setting may not 
provide reliable information about the standard deviation of the primary endpoint 
in this particular population (outpatients receiving maintenance dialysis), no 
formal power calculation was applied. The sample size corresponds to the sample 
size of previous feasibility closed-loop randomized trials9,11.
Study endpoints. The primary endpoint was the percentage of time the sensor 
glucose measurement was in the target glucose range of 5.6–10.0 mmol l−1 during 
the 20-day study period. This target glucose range was selected in line with 
recommendations for less stringent glucose control in this population due to their 
high risk for hypoglycemia and related adverse events5,6,21–23.
Other key endpoints are the percentage of time spent with sensor glucose 
above 10.0 mmol l−1, mean sensor glucose and the percentage of time spent with 
sensor glucose below 3.9 mmol l−1. Secondary efficacy endpoints included time 
spent with sensor glucose below 5.6 mmol l−1 and below 3.0 mmol l−1, time spent 
with sensor glucose levels in severe hyperglycemia (>20 mmol l−1) and the total 
daily insulin dose. Glucose variability was evaluated by the standard deviation 
and the coefficient of variation of sensor glucose utilizing data collected from the 
whole study period. The between-day coefficient of variation of sensor glucose was 
calculated from daily mean glucose values (0:00–23:59).
Safety endpoints included severe hypoglycemia (capillary glucose <2.2 mmol l−1 
or requiring assistance of another person), along with other adverse events and 
serious adverse events and device deficiencies.
Exploratory analyses included a subset of glucose and insulin metrics during 
the first seven days and during the subsequent period of day 8 to day 20 (time 
in target, time above target, time in hypoglycemia (<3.9 mmol l−1), mean sensor 
glucose, standard deviation and the coefficient of variation of sensor glucose, and 
total daily insulin dose) to limit the number of comparisons. Variability of glucose 
and insulin requirements between dialysis and non-dialysis days was assessed using 
the coefficient of variation of sensor glucose and insulin requirements between 
dialysis days (0:00–23:59) and non-dialysis days (0:00–23:59). Mean inter-dialytic 
weight gain was calculated for each study period.
Psychosocial assessments were measured using questionnaires collected at the 
end of each study period and closed-loop participants’ experience at the end of the 
closed-loop period.
Statistical analysis. The statistical analysis plan was agreed by the investigators 
in advance. All analyses were carried out on an intention-to-treat basis. We 
analyzed endpoints from participants with at least 48 h of sensor glucose data in 
both study periods. The respective values obtained during the 20-day randomized 
interventions were compared.
Values are reported as mean ± s.d. for normally distributed values or median 
(interquartile range) for non-normally distributed values. A two-sample t-test 
on paired differences was used to compare normally distributed variables24 and 
the Mann–Whitney–Wilcoxon rank-sum test for data that are not normally 
distributed. No allowance was made for multiplicity. Outcomes were calculated 
using GStat software, version 2.3 (University of Cambridge), and statistical  
analyses were performed using SPSS, version 27 (IBM Software). All P values  
are two-tailed, and P values of less than 0.05 were considered to indicate  
statistical significance.
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Nature Research Reporting Summary linked to this Article.
Data availability
The data that support the findings of this study are available from the corresponding 
author for the purposes of advancing the management and treatment of diabetes. 
All data shared will be de-identified. The study protocol is available with this paper.
Code availability
The control algorithm cannot be made publicly available because it is proprietary 
intellectual property. The control algorithm cannot be used in routine practice in 
the outpatient setting as regulatory approval has not yet been granted.
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Extended Data Fig. 1 | CamAPS HX fully automated closed-loop insulin delivery system. CamAPS HX fully automated closed-loop insulin delivery system.
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Extended Data Fig. 2 | The relationship between closed-loop target glucose settings and glucose outcomes. The relationship between closed-loop  
target glucose settings and (i) time in target glucose range 5.6 to 10.0 mmol/L (the blue full circle) and (ii) time in hypoglycaemia below 3.9 mmol/L  
(the black full circle).
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Data collection The CamAPS HX closed-loop app (CamDiab, Cambridge, UK) resides on an unlocked Android phone, receives sensor glucose data from a 
Dexcom G6 transmitter (Dexcom, San Diego, CA, USA), and uses Cambridge adaptive model predictive control algorithm (version  0.3.71) to 
direct insulin delivery on a Dana Diabecare RS pump (Diabecare, Sooil, South Korea). Sensor glucose and insulin data were obtained from the 
Diasend/Glooko (https://diasend.com//en) data management platform.
Data analysis Outcomes were calculated using GStat software, version 2.3 (University of Cambridge), and statistical analyses were performed using SPSS, 
version 27 (IBM Software, Hampshire, UK). 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and 
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
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All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The data that support the findings of this study are available from the corresponding author for the purposes of advancing management and treatment of diabetes. 
All data shared will be de-identified. Study protocol is available with publication.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size This was an exploratory study aiming for 32 subjects with at least 48 hours of data. Since previous studies using closed-loop in an inpatient 
setting may not provide reliable information about the standard deviation of the primary endpoint in this particular population (outpatients 
receiving maintenance dialysis), no formal power calculation was applied. The sample size corresponds to the sample size of previous 
feasibility closed-loop randomised trials (9,11). 
Data exclusions All analyses were carried out on an intention-to-treat basis. We analysed end points from participants with at least 48 h of sensor glucose data 
in both study periods. Of 27 randomized participants, one participant was withdrawn from the study post-randomisation as they required 
hospital admission and died before the start of the first intervention period (control). Two participants stopped a study period early; one 
during the second period (control) due to bereavement and one during the first period (closed-loop) due to local covid-19 restrictions. These 
participants both completed a minimum of 48 hours in both study periods and were included in the analysis.
Replication The current manuscript reports the results of a clinical trial. The methods have been described in detail s in the text and study protocol to 
allow replication
Randomization Eligible participants were randomly assigned to either initial use of fully closed-loop glucose control with faster acting insulin aspart for 20 
days followed by standard multiple daily insulin injection therapy for 20 days or vice versa. Randomisation was done using a computer-
generated sequence with a permuted block design (block size 4) and stratified by centre.
Blinding Participants and investigators were not masked to the intervention being used during each period due to the nature of the interventions 
precluding the ability to mask.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems




Animals and other organisms
Human research participants
Clinical data
Dual use research of concern
Methods





Policy information about studies involving human research participants
Population characteristics From 21 October 2019 to 3 November 2020, 27 participants were enrolled and randomised (17 men, 9 women,  average age 
68±11 years [mean ±SD] and average diabetes duration 20±10 years).
Recruitment Participants were recruited from dialysis centres and nephrology and diabetes outpatient clinics at Addenbrooke’s Hospital in 
Cambridge, United Kingdom, and Inselspital, University Hospital of Bern, Switzerland. Inclusion criteria included age 18 years 
and older, type 2 diabetes requiring subcutaneous insulin therapy and end stage renal failure requiring maintenance dialysis 
(haemodialysis or peritoneal dialysis). Exclusion criteria included type 1 diabetes, pregnancy or breast-feeding, severe visual 
or hearing impairment and any physical or psychological disease or the use of medication(s) likely to interfere with the 
conduct of the trial or interpretation of the results.  
Recruitment rate was approximately 50% of those who were approached and eligible to participate in the study and included 
only one participant using peritoneal dialysis, which may limit generalisablity of the findings.
Ethics oversight The study protocol was approved by the local Research Ethics Committees (London – Stanmore Ethics Committee, UK, and 
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Ethics oversight Ethics Committee Bern, Switzerland) and Regulatory Authorities (MHRA and Swissmedic). The safety aspects of the trial were 
overseen by an independent Data and Safety Monitoring Board. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration The study was registered with ClinicalTrials.gov NCT04025775.
Study protocol Study protocol is available with publication
Data collection Participants were enrolled and randomised from 21 October 2019 to 3 November 2020 at Addenbrooke’s Hospital in Cambridge, 
United Kingdom, and Inselspital, University Hospital of Bern, Switzerland. Participant demographics and medical history, body weight 
and height, glycated haemoglobin (HbA1c) and total daily insulin dose were recorded at enrolment. Study visits were undertaken at 
the hospital or local dialysis centre. 
Participants were randomly assigned to either initial use of fully closed-loop glucose control with faster acting insulin aspart for 20 
days followed by standard multiple daily insulin injection therapy for 20 days or vice versa. Glycaemic and insulin endpoints were 
collected from each 20-day study period. Sensor glucose and insulin data are automatically uploaded to the Diasend/Glooko data 
management platform. Body weight pre- and post-dialysis was recorded at each dialysis session (or daily if on peritoneal dialysis) 
during each 20-day study period. Psychosocial assessments were measured using questionnaires collected at the end of each study 
period. 
Outcomes The primary endpoint was the percentage of time the sensor glucose measurement was in the target glucose range of 5.6 to 10.0 
mmol/L during the 20-day study period. This target glucose range was selected in line with recommendations for less stringent 
glucose control in this population due to their high risk for hypoglycaemia and related adverse events (5, 6, 16-18).  
Other key endpoints are the percentage of time spent with sensor glucose above 10.0 mmol/L, mean sensor glucose, and the 
percentage of time spent with sensor glucose below 3.9 mmol/L. Secondary efficacy endpoints included time spent with sensor 
glucose below 5.6 mmol/L and below 3.0 mmol/L, time spent with sensor glucose levels in significant hyperglycaemia (>20mmol/L) 
and the total daily insulin dose. Glucose variability was evaluated by the standard deviation and the coefficient of variation of sensor 
glucose utilising data collected from the whole study period. The between-day coefficient of variation of sensor glucose was 
calculated from daily mean glucose values (0000-2359).  
Safety end-points included severe hypoglycaemia (capillary glucose <2.2 mmol/L, or requiring assistance of another person), along 
with other adverse events and serious adverse events and device deficiencies. 
Exploratory analyses included a subset of glucose and insulin metrics during the first 7 days and during the subsequent period of day 
8 to day 20 (time in target, time above target, time in hypoglycaemia (<3.9 mmol/L), mean sensor glucose, standard deviation and 
the coefficient of variation of sensor glucose, and total daily insulin dose) to limit the number of comparisons. Variability of glucose 
and insulin requirements between dialysis and non-dialysis days was assessed using coefficient of variation of sensor glucose and 
insulin requirements between dialysis days (0000-2359) and non-dialysis days (0000-2359). Mean inter-dialytic weight gain was 
calculated for each study period. 
Psychosocial assessments were measured using questionnaires collected at the end of each study period and closed-loop 
participants’ experience at the end of the closed-loop period.
